F-1/A: WORK Medical Technology Group LTD Eyes Nasdaq Listing with $8 Million IPO

WORK Medical Technology Group LTD, a Cayman Islands-based medical device supplier in China, plans to raise $8 million through an initial public offering of 2,000,000 Ordinary Shares at an expected price of $4.00 per share.

Summary

• WORK Medical Technology Group LTD, a Cayman Islands holding company, is planning an initial public offering of 2,000,000 Ordinary Shares at an expected price of $4.00 per share, aiming to list on the Nasdaq Capital Market under the symbol 'WOK'.
• The company conducts its operations through PRC subsidiaries, primarily Work (Hangzhou) Medical Treatment Equipment Co., Ltd., focusing on the development, manufacture, and sale of Class I and II medical devices.
• The IPO is contingent upon final approval from Nasdaq, and there is no guarantee of listing approval or offering consummation.
• The company's revenue model relies on sales of medical devices both domestically (87% of revenue for the six months ended March 31, 2024) and internationally (13% of revenue for the six months ended March 31, 2024), with total revenue of $5,309,095 for the six months ended March 31, 2024.
• The company faces legal and operational risks associated with being based in China, including regulatory uncertainties and potential government intervention.
• The company completed filing procedures with the CSRC on December 21, 2023, in accordance with new administrative rules regarding overseas listings.
• The company's auditor, WWC, P.C., is based in the U.S. and subject to PCAOB inspection, but uncertainties exist regarding the ability to fully cooperate with PCAOB requests without Chinese authorities' approval.
• The company does not expect to pay any cash dividends in the foreseeable future, intending to use available funds for business development and growth.
• The company's sales of masks have decreased from $4,752,892, or approximately 52.74%, for the six months ended March 31, 2023, to approximately $566,549, or approximately 10.67%, for the six months ended March 31, 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed outlook. While the company is pursuing a Nasdaq listing and has growth strategies in place, it faces significant risks related to its operations in China, regulatory uncertainties, and declining sales in key product categories. The financial performance shows a decline in revenue and profit, indicating potential challenges in the near term.

Positives

• The company has a wide distribution network, selling products in 34 provincial-level administrative regions in China and exporting to over 30 countries.
• The company has a sales team of 40 employees and a strict quality management system, with international CE certification and ISO 13485 system certification.
• The company has registered 17 products with the FDA.
• The company has 29 patents in mainland China relating to their products and have 14 pending patent applications.

Negatives

• The company faces legal and operational risks associated with being based in China, including regulatory uncertainties and potential government intervention.
• The company's auditor's ability to fully cooperate with PCAOB requests is uncertain due to recent developments regarding audits of China-based companies.
• The company's sales of masks have decreased significantly due to reduced demand and unit price following the easing of COVID-19 restrictions.
• The company is subject to fire protection laws, and Hangzhou Shanyou has not prepared the required regulatory reports in connection with fire protection laws and regulations, and, as a consequence, may be ordered to stop use of such production lines by PRC regulatory authorities.

Risks

• Changes in PRC government policies or relations between China and the United States may adversely affect the company's business.
• Uncertainties exist regarding the interpretation and enforcement of PRC laws and regulations.
• The PRC government may intervene or influence the company's operations and this offering at any time.
• Additional compliance procedures may be required due to new filing-based administrative rules for overseas offerings by domestic companies in China.
• The company's Ordinary Shares may be delisted under the Holding Foreign Companies Accountable Act if the PCAOB is unable to inspect the company's auditors.
• Failure to maintain the quality and safety of the company's products could have a material and adverse effect on the company's reputation, financial condition and results of operations.
• The company faces the risk of fluctuations in the cost, availability and quality of their raw materials, which could adversely affect their results of operations, and thus, adversely affect the Group as a whole.
• The company does not have long term contracts with their suppliers and the suppliers can reduce order quantities or terminate sales to the company at any time.
• The company industry is intensely competitive.
• If the company fails to timely renew their medical device licenses or registration certificates, it could adversely affect the company and our reputation, financial condition and results of operations.

Future Outlook

The company intends to continue investing in research and development, expand its sales and distribution network, and strengthen its quality control system to develop its business and strengthen brand loyalty.

Industry Context

The medical device industry is intensely competitive, with thousands of companies both domestically and internationally. The Chinese medical device market is growing rapidly, but faces challenges such as import dependence and insufficient R&D investment.

Comparison to Industry Standards

• The global medical device market reached US$552.8 billion in 2022, with the top ten companies accounting for approximately 40.29% of the market.
• In China, the top 10 listed companies in the medical device industry accounted for approximately 10.60% of the market size in 2022, indicating a less concentrated market compared to the global landscape.
• Leading global medical device companies invest significantly in R&D, with investments ranging from $1.03 billion to $14.6 billion in 2022, while leading Chinese companies invest considerably less, ranging from $0.07 billion to $0.42 billion.

Stakeholder Impact

• Shareholders face risks associated with regulatory uncertainties, potential government intervention, and the possibility of delisting.
• Employees may be affected by changes in business operations and financial performance.
• Customers may experience changes in product availability and pricing.
• Suppliers may be affected by changes in the company's procurement strategies.

Next Steps

• Obtain final approval from Nasdaq for listing on the Nasdaq Capital Market.
• Consummate the offering of 2,000,000 Ordinary Shares.
• Implement strategies to mitigate risks and expand business operations.
• Allocate net proceeds from the offering for upgrading production equipment, developing new products, marketing, patent purchases, and working capital.

Key Dates

Keywords

medical devices, IPO, China, Nasdaq, CSRC, PCAOB, regulatory risks, financial performance, Ordinary Shares, WOK